美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

33.21

+0.24580.75%

盤後：33.17-0.0408-0.12%16:10 EDT

成交量：534

成交額：1.77萬

市值：1,328.43萬

市盈率：- -

高：33.21

開：33.11

低：33.11

收：32.97

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.27

換手率：0.13%

股息：0.08

股息率：0.25%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准

石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

百利天恒：宜澤康III期臨床試驗完成首例受試者入組

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段

Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利

Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權

吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？

TradingKey中文

阿斯利康慢阻肺藥物兩項晚期臨床試驗取得成功

环球市场播报

DELPHI‑305 三期臨床試驗達到主要終點。

Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

PHARVARIS的3期臨床試驗達到全部主要及次要終點。

石藥集團：SYH2083滴眼液獲臨床試驗批准

羅兵咸永道、默克與哈希圖集團試點可可溯源系統

膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影

环球市场播报

復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BMED/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.2108,"timestamp":1789416000000,"preClose":32.965,"halted":0,"volume":534,"hourTrading":{"tag":"盘后","latestPrice":33.17,"preClose":33.2108,"latestTime":"16:10 EDT","volume":7,"amount":232.554,"timestamp":1789416603529,"change":-0.0408,"changeRate":-0.001229,"amplitude":0},"delay":0,"changeRate":0.00745639314424376,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"已收盤","change":0.2458,"latestTime":"09-14 16:00:00 EDT","open":33.11,"high":33.2108,"low":33.11,"amount":17725,"amplitude":0.003058,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":32.965,"sharesOutstanding":360000,"nav":32.890304,"aum":13156121.6,"dividendRate":0.002487,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.17,"preClose":33.2108,"latestTime":"16:10 EDT","volume":7,"amount":232.554,"timestamp":1789416603529,"change":-0.0408,"changeRate":-0.001229,"amplitude":0},"volumeRatio":0.273566,"impliedVol":0.068,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.273566,"shares":400000,"dividePrice":0.0826,"high":33.2108,"amplitude":0.003058,"preClose":32.965,"low":33.11,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.2108,"eps":0,"divideRate":0.002487,"volume":534,"delay":0,"ttmEps":0,"open":33.11,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":34.0304,"twentyDayClose":32.17,"sixtyDayClose":28.4912},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666846135","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666846135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","01093","BK1515","IE00BZ08YR35.GBP","LU1226287792.SGD","IE00B031HY20.USD","LU1328277881.USD","PSYK","LU1813983027.USD","SG9999004220.SGD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","IE0008368742.USD","LU1008478684.HKD","LU0326950275.SGD","LU1993786604.SGD","LU0880133367.SGD","LU1226287875.USD","BK1191","LU1152091754.HKD","LU0315179316.USD","LU1807302812.USD","LU1226288253.USD","LU2039709279.SGD","LU0140636845.USD","HK0000165453.HKD","LU1960683339.HKD","BMED","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YT58.USD","BK1521","LU0072913022.USD","LU0067412154.USD","MDTX","IBBQ","KURE","LU1951186391.HKD","LU1152091168.USD","IBBJ","IE0008369823.USD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584690","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584690?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","LU0314109678.HKD","IBBQ","IE00B5MMRT66.SGD","LU1993786604.SGD","IBBJ","LU1226288253.USD","HK0000165453.HKD","LU1960683339.HKD","LU0067412154.USD","IE00B031HY20.USD","LU1226287875.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","MDTX","LU0140636845.USD","BK1191","LU1328277881.USD","BK1521","LU1152091754.HKD","LU0315179316.USD","LU0501845795.SGD","BK1515","BMED","IE00BZ08YR35.GBP","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","PSYK","IE00B543WZ88.USD","IE0008368742.USD","LU0326950275.SGD","01093","LU1226287529.USD","LU1008478684.HKD","KURE","IE00BZ08YT58.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666845175","title":"石藥集團：SYH9102注射液獲中國臨床試驗批准，每月給藥一次","url":"https://stock-news.laohu8.com/highlight/detail?id=2666845175","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666845175?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","PSYK","IBBQ","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666898185","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666898185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666898185?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BMED","PSYK","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589136","title":"百利天恒：宜澤康III期臨床試驗完成首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589136","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589136?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 17:09","pubTimestamp":1788944940,"startTime":"0","endTime":"0","summary":"每经AI快讯，9月9日，百利天恒公告称，公司自主研发的全球首创双抗ADC宜泽康用于不可切除EGFR突变非小细胞肺癌同步放化疗后维持治疗的III期临床试验已完成首例受试者入组。每日经济新闻 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260909/c679746443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BMED","688506","MDTX","BK0239","PSYK","91194","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4139","BK4588","BK4534","IE00B4R5TH58.HKD","LU2468319806.SGD","IE00BJT1NW94.SGD","TBXU","LU2242652126.USD","LU0289739699.SGD","LU0320765992.SGD","PBE","BMED","LU2089984988.USD","BK4533","PJP","LU2112291526.USD","IE00B2B36J28.USD","BK4599","MDTX","LU1571399168.USD","AMGN","LU0868494617.USD","LU1057294990.SGD","IE0002141913.USD","PSYK","IE00BFTCPJ56.SGD","LU0122379950.USD","IE0009355771.USD","IBBQ","LU2242646821.SGD","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4566","IBBJ","LU0889565916.HKD","IBB","LU1023059063.AUD","SG9999001440.SGD","LU1061106388.HKD","BBH","BIB","LU1983299246.USD","BK4585","BK4581","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","SG9999015986.USD","LU1674673428.USD","LU0320765992.SGD","BMED","LU0289739699.SGD","LU1430594728.SGD","IBB","LU1778281490.HKD","SG9999015945.SGD","LU0965509283.SGD","LU1839511570.USD","LU2468319806.SGD","BIB","LU1674673691.USD","LU0889565916.HKD","ASMB","TMED","BK4532","LU0823416689.USD","LU0122379950.USD","LU1571399168.USD","LU1061106388.HKD","LU1057294990.SGD","BK4550","BK4583","LU0058720904.USD","LU2087621335.USD","LU2089984988.USD","LU0965509010.AUD","LU1066053197.SGD","LU0234570918.USD","IE0002270589.USD","LU2357627491.SGD","IE00BSNM7G36.USD","LU1934455194.USD","IE00BZ1G4Q59.USD","GILD","BK4139","LU0965508806.USD","IE00B19Z3581.USD","LU2324357040.USD","LU1934455863.HKD","MEDI","BK4566","BBH","LU1023059063.AUD","BK4578","BK4568","IE00B3T34201.USD","BK4588","LU0859254822.USD","LU1066051498.USD","LU1585245621.USD","LU1934455277.USD","SG9999015952.SGD","BK4585","LU0114720955.EUR","IBBQ","LU0882574055.USD","LU2112291526.USD","IE00B7SZLL34.SGD","LU0109394709.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU0861579265.USD","LU1037948541.HKD","TBXU","LU1037948897.HKD","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154623157","title":"Assembly Biosciences旗下Gs-1179預計2026年底前將推進至生殖器皰疹二期臨床試驗階段","url":"https://stock-news.laohu8.com/highlight/detail?id=1154623157","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154623157?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897731,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前宣布，其研发管线中的候选药物Gs-1179有望在2026年年底之前顺利迈入针对生殖器疱疹的二期临床试验阶段。生殖器疱疹作为一种常见的性传播感染疾病，全球患者群体庞大，对创新疗法的需求十分迫切。Assembly Biosciences正积极加速该药物的研发进程，以期尽早为患者带来新的治疗选择。业内分析人士指出，若Gs-1179能够顺利通过后续试验的严格考验，将可能重塑该适应症的市场格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","LU0965509101.SGD","LU0234570918.USD","LU0823416689.USD","LU2468319806.SGD","ASMB","BK4532","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU0859254822.USD","SG9999015952.SGD","LU1934455194.USD","LU0889565916.HKD","LU1037948541.HKD","LU0965508806.USD","TMED","LU1057294990.SGD","LU0965509283.SGD","LU1934455863.HKD","LU2089984988.USD","SG9999015945.SGD","LU1674673428.USD","LU0114720955.EUR","BIB","LU1778281490.HKD","BK4588","IE00B7SZLL34.SGD","BK4550","LU2087621335.USD","IE00BZ1G4Q59.USD","LU2112291526.USD","LU1674673691.USD","LU1061106388.HKD","BK4566","IE00B19Z3B42.SGD","LU0320765992.SGD","LU1934455277.USD","LU0058720904.USD","LU1571399168.USD","LU0861579265.USD","LU1585245621.USD","IE00B3T34201.USD","IBB","IE00BSNM7G36.USD","MEDI","LU2324357040.USD","BK4578","SG9999015978.USD","IBBQ","LU0965509010.AUD","BBH","TBXU","IE00BKVL7J92.USD","LU0882574055.USD","LU1430594728.SGD","BK4139","LU1023059063.AUD","LU1839511570.USD","BMED","LU0109394709.USD","LU0122379950.USD","IE0002270589.USD","SG9999015986.USD","BK4583","GILD","BK4585","LU1066051498.USD","LU2357627491.SGD","LU1037948897.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115029168","title":"Assembly Biosciences：吉利德獨享HSV HPI項目臨床開發與商業化權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1115029168","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115029168?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897702,"startTime":"0","endTime":"0","summary":"Assembly Biosciences宣布，吉利德科学已保留其HSV HPI项目的独家临床开发及商业化权利。这一决定标志着双方合作进一步深化，吉利德将全权主导该项目的后续推进与市场布局。对于Assembly Biosciences而言，此举不仅明确了合作伙伴的战略优先级，也为其自身聚焦其他管线资源提供了更大灵活性。业内观察人士指出，HSV HPI项目的独家授权，反映了吉利德在抗病毒治疗领域持续加码的雄心，同时也凸显了该类创新疗法在未被满足的医疗需求中所蕴含的巨大潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","SG9999015945.SGD","LU0289739699.SGD","LU1061106388.HKD","TBXU","MEDI","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1934455277.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU0965509283.SGD","LU0859254822.USD","LU1571399168.USD","LU1674673428.USD","LU2089984988.USD","LU0122379950.USD","LU2468319806.SGD","LU0965509010.AUD","BK4578","LU1057294990.SGD","LU1430594728.SGD","LU1066053197.SGD","GILD","LU1585245621.USD","BIB","BK4550","BK4532","BMED","LU1778281490.HKD","LU0234570918.USD","LU1066051498.USD","LU1023059063.AUD","LU0965508806.USD","BK4568","BK4588","LU1674673691.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0882574055.USD","LU1037948541.HKD","IBBQ","LU0965509101.SGD","LU0058720904.USD","BBH","SG9999015986.USD","ASMB","IBB","IE00B19Z3B42.SGD","IE0002270589.USD","LU0109394709.USD","LU0823416689.USD","BK4139","LU2357627491.SGD","LU0320765992.SGD","IE00BZ1G4Q59.USD","SG9999015978.USD","TMED","LU1037948897.HKD","LU1934455863.HKD","SG9999015952.SGD","BK4583","LU2324357040.USD","BK4566","LU1839511570.USD","LU0861579265.USD","LU1934455194.USD","BK4585","LU2112291526.USD","LU2087621335.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179230759","title":"Assembly Biosciences行使與吉利德關於HSV解旋酶-引物酶抑制劑項目的美國利潤分成選擇權","url":"https://stock-news.laohu8.com/highlight/detail?id=1179230759","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179230759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:01","pubTimestamp":1788897669,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司已正式行使与吉利德科学就HSV解旋酶-引物酶抑制剂项目达成的美国利润分成选择权。这一战略举措标志着双方合作进入新阶段，有望加速该抗病毒疗法的临床开发与商业化进程。通过行使该选择权，Assembly Biosciences将能够分享该药物在美国市场的未来收益，同时借助吉利德在抗病毒领域的深厚积累与市场渠道，共同推进这一潜在重磅药物的落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU2357627491.SGD","SG9999015978.USD","LU1066051498.USD","LU1934455194.USD","LU1061106388.HKD","IE00BZ1G4Q59.USD","LU1674673428.USD","TMED","SG9999015952.SGD","IBB","ASMB","LU1023059063.AUD","LU0320765992.SGD","BK4583","BK4588","LU2087621335.USD","BK4585","IBBQ","LU0965509010.AUD","LU1778281490.HKD","LU0965508806.USD","LU1585245621.USD","BK4578","BK4550","IE00B19Z3581.USD","LU0823416689.USD","LU0882574055.USD","LU2089984988.USD","TBXU","LU0289739699.SGD","LU0861579265.USD","LU0965509283.SGD","IE00B7SZLL34.SGD","LU1037948541.HKD","LU1571399168.USD","LU1674673691.USD","SG9999015986.USD","IE0002270589.USD","LU0109394709.USD","LU1430594728.SGD","BK4568","LU0889565916.HKD","LU1934455277.USD","BBH","BMED","LU2112291526.USD","BIB","LU0058720904.USD","LU0859254822.USD","LU1057294990.SGD","IE00B3T34201.USD","MEDI","LU2324357040.USD","LU0114720955.EUR","IE00B19Z3B42.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0965509101.SGD","LU1037948897.HKD","IE00BSNM7G36.USD","LU1839511570.USD","LU2468319806.SGD","LU1066053197.SGD","LU1934455863.HKD","BK4532","GILD","SG9999015945.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374570","title":"吉利德科學(GILD)股票9月8日盤中下跌3.26%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374570","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374570?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 01:16","pubTimestamp":1788887780,"startTime":"0","endTime":"0","summary":"• 吉利德在经历了长达数月的持续上涨后，因获利回吐而出现回调。\n• 强劲的第二季度营收主要受其旗舰 HIV 和 Trodelvy 产品线的推动。\n• 分析师维持“买入”评级，平均目标价为 157.79 美元。","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262156554-market-movers-gild-20260908","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0058720904.USD","IE00BKVL7J92.USD","LU0965509101.SGD","LU2324357040.USD","LU0114720955.EUR","IBB","LU0289739699.SGD","TBXU","IBBQ","BBH","IE00BSNM7G36.USD","LU1839511570.USD","BK4578","LU1674673691.USD","LU1674673428.USD","LU0823416689.USD","LU1571399168.USD","SG9999015952.SGD","IE00B7SZLL34.SGD","MEDI","IE00BZ1G4Q59.USD","SG9999015945.SGD","BMED","GILD","IE0002270589.USD","LU1778281490.HKD","LU1934455277.USD","LU2112291526.USD","IE00B3T34201.USD","TMED","BK4583","IE00B19Z3581.USD","LU0109394709.USD","LU2087621335.USD","LU1430594728.SGD","BIB","LU0122379950.USD","BK4568","LU0861579265.USD","LU1023059063.AUD","LU1037948541.HKD","BK4585","SG9999015978.USD","SG9999015986.USD","LU0965508806.USD","BK4532","IE00B19Z3B42.SGD","LU0859254822.USD","LU0882574055.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665754133","title":"阿斯利康慢阻肺藥物兩項晚期臨床試驗取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2665754133","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665754133?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:45","pubTimestamp":1788875100,"startTime":"0","endTime":"0","summary":"阿斯利康周二公布慢阻肺在研药物两项成功的晚期临床试验完整结果，市场对该药创造数十亿美元营收的预期进一步升温。据阿斯利康数据，美国确诊及未确诊慢阻肺患者合计约 1600 万2600 万人，慢阻肺位列美国第五大死亡原因。阿斯利康近期将该药物销售峰值预期上调至50 亿美元以上，助力公司冲刺 2030 年整体 800 亿美元营收目标。两项临床试验同时纳入现吸烟者、既往吸烟者，覆盖全部嗜酸粒细胞水平、全部肺功能严重程度分级的患者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inircrns9296776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BMED","MDTX","IBBJ","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665373053","title":"DELPHI‑305 三期臨床試驗達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665373053","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665373053?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:19","pubTimestamp":1788873564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","IBBJ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665968376","title":"Tozorakimab在OBERON和TITANIA兩項Ⅲ期臨床試驗中，在降低慢阻肺病急性加重方面均顯示出統計學和臨床意義上的顯著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2665968376","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665968376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:18","pubTimestamp":1788873480,"startTime":"0","endTime":"0","summary":"OBERON和TITANIA两项Ⅲ期试验的结果令人鼓舞，证实tozorakimab在广泛患者人群中均能降低急性加重风险，有望帮助患者摆脱反复急性加重的困扰，获得全新的治疗选择。Tozorakimab 是首个在广泛慢阻肺病患者人群中显示出减少气道黏液栓堵塞作用的生物制剂3。Tozorakimab总体耐受性和安全性良好，唯一报告的药物不良反应为注射部位反应1,2。目前，tozorakimab已在欧盟、中国等主要市场进入上市许可审评阶段，用于治疗慢性阻塞性肺疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5042444_ZH42444_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2237443382.USD","IBBQ","LU2237443895.HKD","LU2456880835.USD","BK4588","BK4568","LU2089984988.USD","LU2462157665.USD","LU0058720904.USD","AZN","BMED","LU2237443465.HKD","LU0708994859.HKD","IBBJ","BK4007","LU2468319806.SGD","LU0289739699.SGD","MDTX","LU0128525929.USD","LU0889565916.HKD","LU2236285917.USD","IE00B3T34201.USD","LU2237443549.SGD","LU0432979614.USD","LU1829250122.USD","AZNH","BK4585","LU2237443622.USD","LU0109394709.USD","LU0320765992.SGD","PSYK","LU1267930573.SGD","LU0310800379.SGD","LU2417539215.USD","LU0029864427.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","09939","PSYK","159151","IBBJ","BK1161","MDTX","IBBQ","BK1515","09637","159938","BK1574","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324003","title":"PHARVARIS的3期臨床試驗達到全部主要及次要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324003","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324003?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:53","pubTimestamp":1788864791,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","BMED","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329150","title":"石藥集團：SYH2083滴眼液獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329150?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:51","pubTimestamp":1788861091,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665370321","title":"羅兵咸永道、默克與哈希圖集團試點可可溯源系統","url":"https://stock-news.laohu8.com/highlight/detail?id=2665370321","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665370321?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:48","pubTimestamp":1788860926,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，The Hashgraph Group 与默克公司（Merck）在普华永道德国（PwC Germany）的咨询与实施支持下，正试点一套可可溯源解决方案。该方案将默克的 M-Trust 物理认证技术与基于 Hedera 网络的 TrackTrace 数字产品护照平台相结合，旨在验证可可从农场到消费者的产地、真实性、质量、召回需求及合规数据。可可属于欧盟《反毁林法规》（EUDR）覆盖的七种商品之一。根据 2025 年 12 月达成的再次延期安排，大型运营商和贸易商须自 2026 年 12 月 30 日起履行相关义务，微型和小型运营商则从 2027 年 6 月 30 日起适用。该方案还对标欧盟《可持续产品生态设计法规》（ESPR）下数字产品护照的推进方向，不过食品和饲料目前被明确排除在 ESPR 范围之外，对可可而言，EUDR 尽职调查仍是近期约束性要求。合作伙伴表示，该架构不限于可可，未来可扩展至药品、奢侈品和工业组件等领域。普华永道德国企业区块链业务负责人 Husen Kapasi 指出，该方案具备可验证性，在食品召回或合规调查中能够发挥关键作用。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2288251","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0098860793.USD","JDOC","LU1699723380.USD","LU1941712348.USD","LU2491049909.HKD","LU0106261372.USD","RXL","SG9999013999.USD","LU0689626769.HKD","BK4533","LU1571399168.USD","LU0980610538.SGD","XLV","LU0868494708.USD","LU0070302665.USD","LU0234572021.USD","LU2324357040.USD","LU0208291251.USD","BK4588","SG9999002224.SGD","LU0861579265.USD","LU1037948541.HKD","SG9999015358.SGD","BK4516","IE000M9KFDE8.USD","SG9999002232.USD","BK4534","LU0320765646.SGD","IE00BJT1NW94.SGD","FHLC","LU2125909593.SGD","FTXH","LU2023250504.SGD","LU0124676726.USD","LU0130517989.USD","LU0238689110.USD","LU1093756325.SGD","LU1057294990.SGD","LU1989771016.USD","LU2125909247.SGD","LU2089984988.USD","LU1116320737.USD","LU0432979614.USD","LU0211331839.USD","IE00BBT3K403.USD","IE00BJJMRZ35.SGD","LU1974910355.USD","LU1934455863.HKD","LU1989772840.SGD","LU1066051811.HKD","IE00BLSP4452.SGD","LU0985320562.USD","LU1291159041.SGD","SG9999015341.SGD","SGXZ57979304.SGD","LU2433249047.HKD","LU0965509101.SGD","SG9999014567.USD","LU1037948897.HKD","LU1929549753.HKD","LU0868494617.USD","BMED","LU0289739699.SGD","LU2023250843.SGD","LU2361044949.HKD","LU2106854487.HKD","IE00B1BXHZ80.USD","GDOC","LU1035773651.USD","SG9999001176.USD","LU2360032135.SGD","LU1923622614.USD","LU0965509010.AUD","LU1941712264.USD","MRK","PAWZ","LU1989772923.USD","PPH","LU1934455194.USD","LU0965508806.USD","IXJ","LU2491050071.SGD","LU2125154778.USD","SG9999001440.SGD","LU0006306889.USD","LU1032466523.USD","IE00BLSP4239.USD","LU1917777945.USD","SG9999014559.SGD","VHT","LU2361045086.USD","IE00B4R5TH58.HKD","TRUH","LU0265550359.USD","LU0320765489.SGD","LU0265550946.USD","SG9999001176.SGD","IHE","BK4007","SG9999014575.USD","LU1201861249.SGD","LU1430594728.SGD","HRTS","LU0965509283.SGD","LU0130102774.USD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU0477156953.USD","LU0823416689.USD","LU0122379950.USD","LU1061106388.HKD","BK4550","LU0058720904.USD","LU0203347892.USD","LU0648001328.SGD","LU1066053197.SGD","IE0009355771.USD","LU2357627491.SGD","LU0266013472.USD","IE00BSNM7G36.USD","LU2125154935.USD","IE0002141913.USD","LU2491050154.USD","BK4559","LU0203345920.USD","LU1066051225.USD","LU1983299246.USD","LU2361044865.SGD","LU1023059063.AUD","LU0859254822.USD","LU1585245621.USD","LU1066051498.USD","LU1162221912.USD","LU1934455277.USD","LU2461242641.AUD","BK4585","LU1093756168.USD","SG9999014542.SGD","LU1069347547.HKD","LU2112291526.USD","LU0942090050.USD","IE00BN8TJ469.HKD","LU1116320901.HKD","IYH","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665329827","title":"膽固醇藥物臨床試驗受挫，數十億美元研發競賽蒙上陰影","url":"https://stock-news.laohu8.com/highlight/detail?id=2665329827","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665329827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:33","pubTimestamp":1788859980,"startTime":"0","endTime":"0","summary":"受该消息影响，诺华周一股价下跌 3%。诺华表示完整试验结果将在后续医学学术大会上公布。诺华强调，本次 8000 多名受试者均已接受最优标准治疗。诺华失利，安进与礼来压力陡增此前分析师测算，如果 pelacarsen 临床试验成功，其销售峰值有望达到每年 4050 亿美元。但该临床试验的冲击不止波及诺华一家。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-08/doc-inirceww4625928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["PSYK","BMED","IBBJ","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665132698","title":"復星醫藥(600196.SH)子公司FXS5626片獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665132698","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665132698?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 17:13","pubTimestamp":1788858794,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复星医药产业发展有限公司收到国家药品监督管理局关于同意FXS5626片用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验的批准。复星医药产业拟于条件具备后于中国境内开展该药品的相关临床研究。截至2026年8月，公司现阶段针对FXS5626的累计研发投入约为1.08亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK0188","BK0028","BK0196","BMED","BK0060","BK0175","BK0239","IBBQ","BK0187","BK1515","PSYK","MDTX","600196","02196","IBBJ","BK1593","BK0096","BK0012","BK0183"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}